Bastiaan Sallevelt

68 CHAPTER 2.2 Table 1. Continued. Barriers Example a (clarity rating, %) Disease - Diseases clearly described, the target population could be easily identified STOPP H9. …in patients with a current or recent history of upper gastrointestinal disease i.e. dysphagia, oesophagitis, gastritis, duodenitis, or peptic ulcer disease, or upper gastrointestinal bleeding (92%) START C4. …for primary open-angle glaucoma. (100%) Signs - Signs clearly described as scores or measurements and therefore unambiguous START B3. …with documented chronic hypoxaemia (i.e. pO2 < 8.0 kPa or 60 mmHg or SaO2 < 89%) (92%) Symptom - Symptoms clearly and unambiguous described STOPP F1. …with parkinsonism (92%) Laboratory findings - Clear cut-off levels with reference ranges present STOPP E6. …if eGFR < 30 ml/min/1.73m2 (100%) EXPLANATION Risk of discontinuing clearly described STOPP D5. …(no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines should be withdrawn gradually if taken for > 2 weeks as there is a risk of causing a benzodiazepine withdrawal syndrome if stopped abruptly) (100%) START N/A aThe examples shown are selected from elements with low and moderate (≤67.7%) clarity ratings for barriers and from high (>67.7%) clarity ratings for facilitators to substantiate the main findings. An overview of all clarity ratings can be found in the Supplementary Information SI1. eGFR = estimated glomerular filtration rate; N/A = not applicable; pO2 = partial pressure of oxygen; SaO2 = arterial oxygen saturation; STOPP/START = Screening Tool of Older Persons’ Prescriptions/Screening Tool to Alert to Right Treatment. F cilitators a (clarity rating, %)